PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma
- 7 February 2006
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 208 (5) , 615-623
Abstract
Chondrosarcomas represent 20% of all primary bone sarcomas, and many studies have attempted to unravel molecular targets for future development of new therapies. The aim of this study was to investigate the expression/activation of PDGFRα, PDGFRβ and KIT receptor tyrosine kinases (RTKs) as potential therapeutic targets in conventional central primary chondrosarcomas (CCS). The expression of PDGFRα, PDGFRβ and KIT RTKs was detected in 16 CCSs using immunohistochemistry (IHC), and their level of expression and activation status were analysed by immunoprecipitation and western blot experiments. PDGFRα, PDGFRβ and KIT cDNAs were screened to verify the presence of activating mutations and the presence of the cognate ligands was analysed by means of RT‐PCR. RTK gene amplification was further studied by means of fluorescence in situ hybridization (FISH) analysis. The immunophenotyping and biochemical analyses showed that the CCSs co‐expressed PDGFRα and PDGFRβ, with the latter showing definitively greater protein expression and phosphorylation levels. PDGFRβ was expressed but not activated in control healthy joint cartilage, in line with no PDGFB detection. Conversely, the KIT gene product did not seem to play a relevant role. These findings, in the absence of activating mutations or an abnormal genomic profile and the presence of PDGFA and PDGFB expression, are consistent with an autocrine/paracrine loop activation of the corresponding receptors. The CCS gene profile described here offers a rationale for the use of RTK inhibitors alone or in combination with chemotherapy, and supports further investigation of RTKs and their downstream signals. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing gradeThe Journal of Pathology, 2005
- 9p21 locus analysis in high‐risk gastrointestinal stromal tumors characterized for c‐kit and platelet‐derived growth factor receptor α gene alterationsCancer, 2005
- Tyrosine Phosphorylation and Endothelial Cell Barrier RegulationThe American Journal of Pathology, 2005
- Chemosensitization by STI571 targeting the platelet‐derived growth factor/platelet‐derived growth factor receptor‐signaling pathway in the tumor progression and angiogenesis of gastric carcinomaCancer, 2005
- Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomasThe Journal of Pathology, 2005
- Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung CancerClinical Cancer Research, 2004
- Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial SarcomaClinical Cancer Research, 2004
- Grade 2 Chondrosarcoma: Stage I or Stage II Tumor?Clinical Orthopaedics and Related Research, 2003
- Platelet-Derived Growth Factor-α Receptor Expression Supports the Growth of Conventional Chondrosarcoma and Is Associated With Adverse OutcomeAmerican Journal of Surgical Pathology, 2001
- Evidence for Distinct Signaling Properties and Biological Responses Induced by the PDGF Receptor α and β SubtypesGrowth Factors, 1999